The present disclosure provides compositions with a modulating gene expression and methods for modulating transcription.

Provided is a plant or plant part comprising a polynucleotide encoding a mutated TriA polypeptide. The expression of said polynucleotide confers to the plant or plant part tolerance to herbicides.

The invention generally relates to methods of producing loline alkaloids or precursors thereof, expression constructs, and host cells useful for producing loline alkaloids or precursors thereof, and methods for producing loline alkaloids or precursors thereof in a host cell.

The invention generally relates to methods of producing loline alkaloids or precursors thereof, expression constructs, and host cells useful for producing loline alkaloids or precursors thereof, and methods for producing loline alkaloids or precursors thereof in a host cell.

A structure adapted to traverse a fluid environment exerting an ambient fluid pressure is provided. The structure includes an elongate body extending from a root to a wingtip and encapsulating at least one interior volume containing an interior fluid exerting an interior fluid pressure that is different from the ambient fluid pressure. A method of retrofitting a structure adapted to traverse a fluid environment exerting an ambient fluid pressure, the structure comprising an elongate body extending from a root to a wingtip and having at least one interior volume is also provided. The method includes sealing the elongate body to encapsulate the at least one interior volume containing an interior fluid; associating at least one valve with the at least one interior volume; and modifying interior fluid content via the at least one valve to produce an interior fluid pressure that is different from the ambient fluid pressure.

A structure adapted to traverse a fluid environment exerting an ambient fluid pressure is provided. The structure includes an elongate body extending from a root to a wingtip and encapsulating at least one interior volume containing an interior fluid exerting an interior fluid pressure that is different from the ambient fluid pressure. A method of retrofitting a structure adapted to traverse a fluid environment exerting an ambient fluid pressure, the structure comprising an elongate body extending from a root to a wingtip and having at least one interior volume is also provided. The method includes sealing the elongate body to encapsulate the at least one interior volume containing an interior fluid; associating at least one valve with the at least one interior volume; and modifying interior fluid content via the at least one valve to produce an interior fluid pressure that is different from the ambient fluid pressure.

This invention relates to polynucleotides comprising optimized aspartylglucosaminidase (AGA) open reading frames and vectors and cells comprising the same. The invention further relates to methods of using the same for delivery of the open reading frame to a cell or a subject and methods for treating aspartylglucosaminuria (AGU) in a subject.

Described herein are compounds and methods for tethering proteins. For example, dimers of Protein X listed in Table 1 are described, where the dimers are formed by the covalent bonding of a cysteine on the first monomer to a cysteine on the second monomer via a cyclic disulfide linker. The covalently attached dimers exhibit increased stabilization and can be used to treat neurodegenerative diseases (such as, for example, Parkinson's Disease, ALS, Alzheimer's Disease, Huntington's Disease, Epilepsy, Frontotemporal Dementia, and/or DMD), cancer, autoimmune disease, and/or Celiac disease.

Described herein are compounds and methods for tethering proteins. For example, dimers of Protein X listed in Table 1 are described, where the dimers are formed by the covalent bonding of a cysteine on the first monomer to a cysteine on the second monomer via a cyclic disulfide linker. The covalently attached dimers exhibit increased stabilization and can be used to treat neurodegenerative diseases (such as, for example, Parkinson's Disease, ALS, Alzheimer's Disease, Huntington's Disease, Epilepsy, Frontotemporal Dementia, and/or DMD), cancer, autoimmune disease, and/or Celiac disease.

The present disclosure relates generally to the use of sphingolipid-metabolizing proteins to mitigate or minimize tissue damage resulting from injury or from disease, for example, pulmonary arterial hypertension (PAH) when the sphingolipid-metabolizing protein is delivered via expression from an Anc80 vector.